Anika Therapeutics | ANIK - Cost Of Sales


Anika Therapeutics reported $11.44M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Abbott USD 5.94B 642M Jun/2026
Agenus USD 642K 399K Sep/2025
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Anika Therapeutics USD 11.44M 797K Dec/2025
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Heron Therapeutics USD 11.12M 795K Dec/2025
Insmed USD 49.5M 3.34M Mar/2026
Integra LifeSciences USD 178.71M 14.73M Mar/2026
Intrexon USD 1.01M 344K Jun/2024
J&J USD 8B 67M Jun/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Ligand Pharmaceuticals USD 11.37M 8.38M Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
Merit Medical Systems USD 197.08M 1.5M Mar/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.67B 621M Mar/2026
Smith & Nephew USD 870M 17M Dec/2025
Stryker USD 2.36B 325M Mar/2026
Veracyte USD 38.49M 794K Mar/2026
Xencor USD 61.66M 50.95M Jun/2025
Zimmer Biomet Holdings USD 738.3M 231.8M Mar/2026